CXCL13 levels are elevated in patients with Waldenstrom's Macroglobulinemia, and are predictive of major response to ibrutinib.

Josephine M Vos, Nickolas Tsakmaklis, Christopher J Patterson, Kirsten Meid, Jorge J. Castillo, Philip Brodsky, Tomas Ganz, Steven T Pals, Marie José Kersten, Lian Xu, Guang Yang, Steven P Treon, and Zachary R. Hunter

Disclosures: This work was supported by the ZonMw (PM Rare program), the International Waldenstrom Macroglobulinemia Foundation, the Leukemia and Lymphoma Society as well as Edward and Linda Nelson Foundation. JJC has received honoraria and/or funding research from Abbvie, Biogen Idec, Gilead, Janssen and Pharmacycics. TG has received honoraria and/or funding research from Intrinsic LifeSciences, LLC (consultant, shareholder, scientific founder), Silarus Pharma (consultant, scientific founder, shareholder), Keryx Pharma (consultant, grant recipient), Vifor (consultant), Akebia (consultant), La Jolla Pharmaceuticals (consultant, joint patent application). SPT received research support and consulting fees from Pharmacycics and Janssen. MJK has consulted for or received compensation for presentations from Gilead, Celgene, Novartis, Roche, Millennium/Takeda, Kite Pharma and BMS, and has received research support from Celgene, Roche, Millennium and Sanofi. The other authors reported no disclosures. There are no patents, whether planned, pending or issued, broadly relevant to the work.

Contributions: ST, ZH, JV, NT, MJK, CP and GY designed the study. JV, ZH, PB, NT, TG, KM, LX performed the research. JV, ZH performed data analysis. JV, ZH, ST, SP, MJK wrote the manuscript. ZH, ST, SP, MJK supervised the study.